Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements

• Status: Completed
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to assess whether myocardial perfusion reserve, measured during routine clinically ordered regadenoson stress cardiac magnetic resonance (CMR) has prognostic value in predicting adverse cardiovascular events. Myocardial perfusion reserve will be measured with CMR by assessing blood flow through the coronary-sinus - the primary vein in the heart.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Illinois at Chicago
• Collaborator: Astellas Pharma Inc
• Treatments: Regadenoson

Criteria

Inclusion Criteria:

• Age ≥18

• Male or Female

• Referred for clinical cardiac magnetic resonance stress testing (with Regadenoson) at the University of Illinois Hospital & Health Sciences System by their healthcare provider as part of their routine clinical care for known or suspected coronary artery disease.

Exclusion Criteria:

• Presence of metallic implants contraindicated with cardiac magnetic resonance (e.g. implantable cardiac defibrillator, pacemaker)

• Glomerular Filtration Rate (GFR) <30ml/min

• High degree atrio-ventricular block

• Hypersensitivity to Regadenoson

• Severe active wheezing from asthma

• Severe claustrophobia